Dipeptide

BrainMD Launches Revolutionary Smart Collagen Supplement for Optimal Brain, Skin & Joint Health

Retrieved on: 
Thursday, February 22, 2024
Dipeptide, Health, Science, Taste, OG, Elasticity, Brain, Skin, Meal, Food, Coffee, Tanning (leather)

LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- BrainMD, the leading provider of premier brain health supplements, proudly announces the release of their revolutionary new product – Smart Collagen .

Key Points: 
  • LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- BrainMD, the leading provider of premier brain health supplements, proudly announces the release of their revolutionary new product – Smart Collagen .
  • In the health and beauty market, collagen's ability to promote skin vitality and joint mobility is well-documented.
  • Remarkably, these collagen peptides also offer profound benefits for cognitive function, establishing Smart Collagen as a standout product for brain health and well-being.
  • "If you're looking for a collagen supplement, choose the one that's backed by science and delivers up to 30x the level of standard collagen peptides: Smart Collagen.

Global Peptide Therapeutics Market & Clinical Trials Insight Report 2022: Market Set to Surpass US$ 75 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 6, 2022
Health, Pharmaceutical, Dermatology, Peptide therapeutics, US, Gastroenterology, Company, Bone, Peptide, Endocrinology, Contract, Prevalence, Indication, Insulin, Attention, Degenerative disease, Cancer, Diabetes, Therapy, Industry, Conditional sentence, Vaccine, Glucagon-like peptide-2, Genentech, Organic acid, Research, Lists of diseases, Growth, Sexual dysfunction, Fine chemical, Neuropeptide, Glycopeptide, Natriuresis, Dipeptide, Depsipeptide, Oligopeptide, Lipopeptide

The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests a promising future of peptide therapeutics in the forthcoming years.
  • Keeping the clinical pipeline into consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028.
  • Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report highlights:
    Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
    Peptide Therapeutics in Clinical trials: > 800 Drugs
    Peptide Therapeutics Commercially Available In Market: > 200 Drugs
    Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides

908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications

Retrieved on: 
Thursday, April 21, 2022
Research, Technology, Software, Stem Cells, Biotechnology, Hardware, General Health, Pharmaceutical, Health, Science, Government, High Value Manufacturing Catapult, Organic acid, CHO, Â, U.S. Securities and Exchange Commission, Device, Team leader, Security (finance), Chinese hamster, Research, TrafFix Devices, Inc. v. Marketing Displays, Inc., Mass spectrometry, MASS, CPI, Science, Private Securities Litigation Reform Act, Automation, Amine, Ambre Energy, Machine learning, Sartorius AG, Growth, Efficiency, Invention, Food, Time, Technology, Sutro Biopharma, Nasdaq, Company, SEC, Cell, Mab, Industry, Dipeptide, Digital technology, Fine chemical, 3D printing

CPI researchers are utilizing 908 Devices REBEL desktop device for at-line cell culture media analysis, helping to identify and then control key process parameters in bioprocessing workflows.

Key Points: 
  • CPI researchers are utilizing 908 Devices REBEL desktop device for at-line cell culture media analysis, helping to identify and then control key process parameters in bioprocessing workflows.
  • The need for more data and analytics along with automation for improved process monitoring and control is often referred to as Biopharma 4.0.
  • Together, 908 Devices and CPI scientists are implementing at-line media analysis for a CHO (Chinese Hamster Ovary) cell line expressing a monoclonal antibody (mAb) in small volume Ambr15 cell culture bioreactor systems through to process scale-up in an Ambr 250 and 10-Liter bioreactors.
  • Time course data from the REBEL provides significant information and insights into the cell metabolism, in addition to typical cell culture parameters such as cell count, viability, and basic metabolite data.

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

Retrieved on: 
Monday, March 28, 2022
Private Securities Litigation Reform Act, Risk, Research, SEC, Biotechnology, Pathology, Probability, Nobel Prize, Knowledge, Twitter, Goal, Nasdaq, Climate, Intellectual property, GLOBE, AES, Disease, Drug development, Health, U.S. Securities and Exchange Commission, Science, IONS, ALS Functional Rating Scale - Revised, Dipeptide, Toxicity, Therapy, Neuroscience, Annual report, ALS, Failure, C9orf72, Social media, Patient, Company, LinkedIn, Headache, Lists of diseases, Multiple sclerosis, Form 10-K, Spinal muscular atrophy, ASO, Judgement, RNA, Safety, BIIB, COVID-19, News, YouTube, Vaccine, Pharmaceutical industry, Biogen, Ionis, Facebook

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued

Key Points: 
  • BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued
    CAMBRIDGE, Mass.
  • and CARLSBAD, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
  • Based on these results, the BIIB078 clinical development program will be discontinued, including its ongoing open-label extension study.
  • This Phase 1 study was a randomized, placebo-controlled, dose-escalating trial to evaluate BIIB078administered intrathecally to adults (n=106) with C9orf72-associated ALS.

908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

Retrieved on: 
Friday, January 7, 2022
Science, Other Science, Biotechnology, Research, Hardware, General Health, Health, Technology, Therapy, Research, Company, Forward-looking statement, Analyser, NYSE, U.S. Securities and Exchange Commission, Security (finance), Organic acid, Private Securities Litigation Reform Act, CEO, GSK, NASDAQ, SEC, Mass spectrometry, Sample, MASS, Bioreactor, Â, Machine learning, Dipeptide, Advanced Micro Devices, Inc. v. Intel Corp., Amine, 3D printing, Fine chemical, GlaxoSmithKline, the REBEL analyzer, 908 Devices, THE REBEL ANALYZER, 908 DEVICES

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL cell culture media analyzer.

Key Points: 
  • 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL cell culture media analyzer.
  • GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.
  • 908 Devices notes there are now 15 customers owning multiple REBEL devices, more than double from one year ago.
  • 908 Devices Inc. (NASDAQ: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.